Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Brink, Mikael ^a   Verheul, Marije K ^b   Rönnelid, Johan ^c   Berglin, Ewa ^a   Holmdahl, Rikard ^d   Toes, Rene ^b   Klareskog, Lars ^d   Trouw, Leendert A ^b   Rantapää Dahlqvist, Solbritt ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMYLATED PROTEIN ANTIBODY; CCP2 ANTIBODY; CITRULLINE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IMMUNOGLOBULIN A;

ALLERGY RAPID TEST; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POPULATION DYNAMICS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SWEDEN; ANIMAL; ASYMPTOMATIC DISEASE; BLOOD; CASE CONTROL STUDY; CHICK EMBRYO; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; RADIOGRAPHY;

ANIMALS; ARTHRITIS, RHEUMATOID; ASYMPTOMATIC DISEASES; AUTOANTIBODIES; AUTOANTIGENS; CASE-CONTROL STUDIES; CHICK EMBRYO; CITRULLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RADIOGRAPHY;

EID: 84924912363     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0536-2     Document Type: Article

References (21)

1. Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12:318-22.
2. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-81.
3. Jorgensen KT, Wiik A, Pedersen M, Hedegaard CJ, Vestergaard BF, Gislefoss RE, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis. 2008;67:860-6.
4. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Ronnelid J, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther. 2011;13:R13.
5. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380-6.
6. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741-9.
7. Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013;65:899-910.
8. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69:1554-61.
9. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65:453-8.
10. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004;63:1085-9.
11. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949-58.
12. Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13:225-30.
13. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108:17372-7.
14. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013;65:911-5.
15. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780-3.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
17. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis. 2005;64:179-82.
18. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther. 2012;14:R201.
19. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med. 2009;206:449-62.
20. Shi J, Willemze A, Janssen GM, van Veelen PA, Drijfhout JW, Cerami A, et al. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method. Ann Rheum Dis. 2013;72:148-50.
21. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73:1761-8.